Ultragenyx Pharmaceutical (RARE) Stock Price, Quote, News & History | Benzinga

Ultragenyx Pharmaceutical Inc (RARE) Stock Price, Quote, News & History

RARENASDAQ

Trade with Public

Trade with Public

$26.75

0.843.24%

Last update: Aug 10, 2:03 PM

Earnings: Q2 2026 Earnings were released on Tue Aug 4th, after the market close

Conference Call: The most recent conference call started at 5:00 PM, 6 days ago

Click to view the webcast

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$25.91

Close

-

Volume / Avg.

1.06M / 2.22M

Day Range

$25.51 - $26.78

52 Wk Range

18.29 - 39.89

Market Cap

$2.64B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

47

Short Interest

14.09%

Days to Cover

6.94

Recent Ultragenyx Pharmaceutical Inc. News

Small Caps Near Record Highs, Robinhood Rallies 12%: Stock Market Today

U.S. stocks traded higher by midday Wednesday, with semiconductor equipment names and small caps leading the tape, as investors held their fire ahead of Kevin Warsh‘s first interest-rate decision as Federal Reserve chair, due at 2 p.m. ET.

Piero Cingari

Jabil Posts Upbeat Q3 Results, Joins Uniqure, Braiin And Other Big Stocks Moving Higher On Wednesday

U.S. stocks rose, with the Dow Jones gaining 200 points on Wed. Jabil Inc (JBL) shares surged 9.8% after beating earnings & revenue estimates. Other big gainers included QURE, CLPT, JLHL, BRAI, LZB, HQ, SHAZ, WNC, RXT, ARQQ, and MFI.

Avi Kapoor

Ultragenyx's Gene Therapy Study Shows Ammonia Reduction In Rare Metabolic Disorder

Ultragenyx Phase 3 gene therapy data shows reduced ammonia levels in rare disease patients, with further results expected in 2027.

Vandana Singh

Why Is Ultragenyx Stock Sinking Friday?

Ultragenyx reports mixed Q4 earnings and initiates strategic restructuring plan to align resources with potential product launches.

Vandana Singh

Ultragenyx Says Gene Therapy Shows Lasting Benefits, Slows Brain Decline In Fatal Childhood Disorder

Ultragenyx reported long-term study data showing lasting brain and skill improvements with UX111 for Sanfilippo syndrome, supporting its resubmitted FDA application ahead of a 2026 decision.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-485.00M

Investing Cash Flow (TTM)

40.00M

Financing Cash Flow (TTM)

397.00M

Free Cash Flow (TTM)

-494.00M

Capital Expenditure (TTM)

-9.00M

Net Change in Cash (TTM)

-

Analyst Trends and Forecast

2

Apr

3

2

May

1

Jul

3

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.91B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

3.63

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-22.51%

Earnings Yield % (FWD)

-15.87%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

-$2.95

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$125.00M

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$25.91

Close

-

Volume / Avg.

1.06M / 2.22M

Day Range

$25.51 - $26.78

52 Wk Range

18.29 - 39.89

Market Cap

$2.64B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

47

Short Interest

14.09%

Days to Cover

6.94

About

Sector

Health Care

Industry

Biotechnology

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic co...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Ultragenyx Pharmaceutical (RARE) stock?

A

You can purchase shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Ultragenyx Pharmaceutical (RARE) competitors?

A

Other companies in Ultragenyx Pharmaceutical’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Ultragenyx Pharmaceutical (RARE) stock?

A

Ultragenyx Pharmaceutical has a consensus price target of $67.77.

Q

What is the current price for Ultragenyx Pharmaceutical (RARE)?

A

The stock price for Ultragenyx Pharmaceutical (NASDAQ: RARE) is $26.75 last updated August 10, 2026 at 2:03 PM EDT.

Q

Does Ultragenyx Pharmaceutical (RARE) pay a dividend?

A

There are no upcoming dividends for Ultragenyx Pharmaceutical.

Q

When is Ultragenyx Pharmaceutical (NASDAQ:RARE) reporting earnings?

A

Ultragenyx Pharmaceutical does not have any upcoming earnings scheduled.

Q

Is Ultragenyx Pharmaceutical (RARE) going to split?

A

There is no upcoming split for Ultragenyx Pharmaceutical.

Q

What sector and industry does Ultragenyx Pharmaceutical (RARE) operate in?

A

Ultragenyx Pharmaceutical is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.